Steven A Fischkoff from 5 Canoe Brook Rd, Short Hills, NJ 07078, age 73, Phone: (973)3760437

Name / Title

Company / Classification

Phones & Addresses

Steven Fischkoff
Vice-President, Vice President Clinical Development

Palatin Technologies, Inc
Mfg of Pharmaceutical Preparations · Pharmaceutical Preparations · Surgical & Medical Instrument Mfg

4 Cedarbrook Dr, East Windsor, NJ 08512
4B Cedarbrook Dr, East Windsor, NJ 08512
4C Cedarbrook Dr, Cranbury, NJ 08512
(609)4952200, (609)4952201

Steven Alan Fischkoff

Steven Fischkoff MD
Internist

5 Canoe Brk Rd, Short Hills, NJ 07078
(973)3317530

Steven Alan Fischkoff
Medical Doctor

Medarex
Biotechnology · Commercial Physical Research · Research & Development in Biotechnology · Research and Development in the Physical, Engineering, and L

Princeton, NJ 08540
707 State Rd, Princeton, NJ 08540
(609)4302880, (609)4302850, (908)7136001

License Records

Steven Alan Fischkoff

Address:

Short Hills, NJ 07078

License #:

MD034568E - Expired

Category:

Medicine

Type:

Medical Physician and Surgeon

Medicine Doctors

Dr. Steven A Fischkoff, Short Hills NJ - MD (Doctor of Medicine)

view source

Specialties:

Oncology
Medical Oncology

Address:

5 Canoe Brook Rd, Short Hills, NJ 07078
(973)3760437 (Phone)

Certifications:

Internal Medicine, 1979
Medical Oncology, 1981

Awards:

Healthgrades Honor Roll

Languages:

English

Education:

Medical School
Perelman School of Medicine University of Pennsylvania
Graduated: 1976
Medical School
Bellevue Hospital Center
Graduated: 1976
Medical School
Baltimore Cancer Rsch Ctr
Graduated: 1976

Steven Alan Fischkoff

view source

Specialties:

Internal Medicine
Medical Oncology
Hematology & Oncology

Education:

University of Pennsylvania(1976)

Us Patents

Treatment Of Sarcoidosis Using Placental Stem Cells
view source
US Patent:

8562973, Oct 22, 2013
Filed:

Apr 6, 2011
Appl. No.:

13/081422
Inventors:

James W. Edinger - Belford NJ, US
Steven Alan Fischkoff - Short Hills NJ, US
Aleksandar Francki - Annandale NJ, US
Vladimir Jankovic - New York NY, US
Bitao Liang - Closter NJ, US
Philippe Martin - Hoboken NJ, US
Cynthia Ray - Branchburg NJ, US
Xiaokui Zhang - Livingston NJ, US
Assignee:

Anthrogenesis Corporation - Warren NJ
International Classification:

C12C 7/04
US Classification:

424 937, 424583
Abstract:

Methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder using placental cells are described. Also describe are kits comprising placental stem cells or a composition thereof that can be used in methods of treating sarcoidosis or a sarcoidosis-related disease or disorder.

Use Of Anti-Tnf Antibodies As Drugs In Treating Septic Disorders Of Anemic Patients
view source
US Patent:

20030012786, Jan 16, 2003
Filed:

May 23, 2002
Appl. No.:

10/154025
Inventors:

Leah Teoh - Wayne NJ, US
William Barchuk - Madison NJ, US
Steven Fischkoff - Short Hills NJ, US
International Classification:

A61K039/395
US Classification:

424/145100
Abstract:

The instant invention is directed to treating an anemic patient having elevated levels of IL-6 by administering a TNF antagonist. It is also directed to treating sepsis in a patient by administering a TNF antagonist.

Use Of Anti-Tnfalpha Antibodies And Another Drug
view source
US Patent:

20030206898, Nov 6, 2003
Filed:

Apr 26, 2002
Appl. No.:

10/133715
Inventors:

Steven Fischkoff - Short Hills NJ, US
Elliot Chartash - Randolph NJ, US
International Classification:

A61K039/395
A61K045/00
C12Q001/70
C12N005/06
C12N005/16
US Classification:

424/130100, 424/143100, 424/281100, 435/005000, 435/345000
Abstract:

The present invention is directed to a method of treating disorders in which TFN activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor (hTNF) in combination with another drug which is useful for treating the disorder. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing are also encompassed by the invention.

Methods Of Administering Anti-Tnfalpha Antibodies
view source
US Patent:

20030235585, Dec 25, 2003
Filed:

Jun 5, 2002
Appl. No.:

10/163657
Inventors:

Steven Fischkoff - Short Hills NJ, US
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US
International Classification:

A61K039/395
US Classification:

424/145100, 424/141100
Abstract:

Methods of treating disorders in which TFN activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor (hTNF) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF (e.g., K=10M or less), a slow off rate for hTNF dissociation (e.g., K=10secor less) and neutralize hTNF activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

Use Of Anti-Tnfalpha Antibodies And Another Drug
view source
US Patent:

20040009172, Jan 15, 2004
Filed:

Apr 24, 2003
Appl. No.:

10/422287
Inventors:

Steven Fischkoff - Short Hills NJ, US
Elliot Chartash - Randolph NJ, US
International Classification:

A61K039/395
A61K031/573
A61K039/145
A61K031/525
A61K031/415
A61K031/192
A61K033/24
A61K031/24
US Classification:

424/145100, 424/649000, 514/171000, 514/570000, 514/537000, 514/406000, 514/251000, 424/209100
Abstract:

The present invention is directed to a method of treating disorders in which TFN activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor (hTNF) in combination with another drug which is useful for treating the disorder. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing are also encompassed by the invention.

Treatment Of Tnfalpha Related Disorders
view source
US Patent:

20040126372, Jul 1, 2004
Filed:

Jul 18, 2003
Appl. No.:

10/622932
Inventors:

Subhashis Banerjee - Shrewsbury MA, US
Lori Taylor - Wadsworth IL, US
Clive Spiegler - Reading, GB
Daniel Tracey - Harvard MA, US
Elliot Chartash - Randolph NJ, US
Rebecca Hoffman - Wilmette IL, US
William Barchuk - Madison NJ, US
Philip Yan - Vernon Hills IL, US
Anwar Murtaza - Westborough MA, US
Jochen Salfeld - North Grafton MA, US
Steven Fischkoff - Short Hills NJ, US
Assignee:

Abbott Biotechnology Ltd. - Hamilton
International Classification:

A61K039/395
US Classification:

424/145100
Abstract:

Methods of treating TNF-related disorders comprising administering TNF inhibitors, including TNF antibodies are described.

Treatment Of Coronary Disorders Using Tnfalpha Inhibitors
view source
US Patent:

20040126373, Jul 1, 2004
Filed:

Jul 18, 2003
Appl. No.:

10/623065
Inventors:

Subhashis Banerjee - Shrewsbury MA, US
Lori Taylor - Wadsworth IL, US
Clive Spiegler - Reading, GB
Daniel Tracey - Harvard MA, US
Elliot Chartash - Randolph NJ, US
Rebecca Hoffman - Wilmette IL, US
William Barchuk - Madison NJ, US
Philip Yan - Vernon Hills IL, US
Anwar Murtaza - Westborough MA, US
Jochen Salfeld - North Grafton MA, US
Steven Fischkoff - Short Hills NJ, US
Assignee:

Abbott Biotechnology Ltd. - Hamilton
International Classification:

A61K039/395
C12Q001/68
US Classification:

424/145100
Abstract:

Methods for treating coronary disease in which TNF activity is detrimental are described.

Treatment Of Pulmonary Disorders Using Tnfalpha Inhibitor
view source
US Patent:

20040131614, Jul 8, 2004
Filed:

Jul 18, 2003
Appl. No.:

10/623076
Inventors:

Subhashis Banerjee - Shrewsbury MA, US
Lori Taylor - Wadsworth IL, US
Clive Spiegler - Reading, GB
Daniel Tracey - Harvard MA, US
Elliot Chartash - Randolph NJ, US
Rebecca Hoffman - Wilmette IL, US
William Barchuk - Madison NJ, US
Philip Yan - Vernon Hills IL, US
Anwar Murtaza - Westborough MA, US
Jochen Salfeld - North Grafton MA, US
Steven Fischkoff - Short Hills NJ, US
Assignee:

Abbott Biotechnology Ltd. - Hamilton
International Classification:

A61K039/395
US Classification:

424/145100
Abstract:

Methods of treating pulmonary disorders comprising administering TNF inhibitors, including TNF antibodies are described.